IPOs are an important tool for raising capital in any industry, but they are especially important in biotech. Cash injections can help companies continue their work and allow financial backers to capture a return on their investment — which frees up funds to invest in other biotech startups. This article from BioSpace highlights some of the most noteworthy recent biotech IPOs.
HoyleCohen’s Ty Summerlin is an expert at navigating the pre and post-IPO landmines to help biotech executives make the most of a windfall. If you’d like to learn more about the intersection between biotech and capital markets, get in touch today!
This article was written by BioSpace, an entity unrelated to HoyleCohen, LLC. The information herein is intended for educational purposes and has been selected by HoyleCohen due to the timeliness of the subject matter.
